Basis: Latest reported fiscal year. Source: stored company filings and market data; unavailable inputs remain N/A.
The enterprise value (EV) is N/A as of Tuesday, October 6, 2026.
ENTERPRISE VALUE (EV)
N/A
Latigo Biotherapeutics Inc.
Market Cap
$1.00B
Enterprise Value (EV)
N/A
| NAME | MARKET CAP | ENTERPRISE VALUE (EV) |
|---|---|---|
| Latigo Biotherapeutics Inc. (LTGO) | $1.00B | N/A |
| LB Pharmaceuticals Inc Common Stock (LBRX)vs › | $997.00M | $719.10M |
| MeiraGTx Holdings plc (MGTX)vs › | $990.00M | $959.15M |
| PROCEPT BioRobotics Corporation (PRCT)vs › | $988.48M | $838.06M |
| Pacira BioSciences, Inc. (PCRX)vs › | $985.34M | $1.19B |
| Aktis Oncology, Inc. (AKTS)vs › | $984.78M | $913.53M |
| Lumexa Imaging Holdings, Inc. Common Stock (LMRI)vs › | $1.03B | $1.93B |
| Immatics N.V. (IMTX)vs › | $1.04B | $787.85M |
| Integra LifeSciences Holdings Corporation (IART)vs › | $1.04B | $2.86B |
| Castle Biosciences, Inc. (CSTL)vs › | $1.04B | $1.01B |
Market Cap
$1.00B
Total Debt
N/A
Cash
N/A
Enterprise Value
N/A
Why use EV instead of Market Cap?
Enterprise Value represents the total value of a company as if you were to acquire it completely - paying for equity while assuming debt and receiving cash.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
